Skripsi
EFEKTIVITAS PEMBERIAN TERAPI TAMBAHAN SAFINAMIDE TERHADAP KOMPLIKASI MOTORIK PENDERITA PENYAKIT PARKINSON DI RS MOHAMMAD HOESIN PALEMBANG
Background: Parkinson's disease is a progressive neurodegenerative disorder characterized by the degeneration of dopaminergic neurons in the substantia nigra. Long-term L-Dopa therapy is associated with the development of motor complications that reduce patients' quality of life. Safinamide is a selective reversible MAO-B inhibitor with an additional mechanism of glutamate release modulation, developed as adjuvant therapy for Parkinson's disease patients with motor complications. This study aimed to analyze the effectiveness of safinamide as adjuvant therapy on motor complications, motor function, and quality of life in Parkinson's disease patients at Mohammad Hoesin Hospital, Palembang. Methods: This was a randomized double-blind controlled trial (RCT) conducted at the Neurology Outpatient Clinic of Mohammad Hoesin Hospital, Palembang, from January to April 2026. A total of 30 Parkinson's disease patients with motor complications were randomized into two treatment groups: the safinamide group (50–100 mg/day) and the control group (placebo), both administered as add-on therapy to routine L-Dopa regimens for 4 weeks. Assessments were performed at baseline and at week 4 using daily ON-time, daily ON-time with no or non troublesome dyskinesia, and daily OFF-time as motor complication parameter in primary outcomes, and UPDRS-II, UPDRS-III, UPDRS-IV as motor function, and PDQ-39 as quality of live in secondary outcomes. Statistical analyses were performed using paired t-test, independent t-test, Mann–Whitney, Chi-square, and Fisher's exact test according to data distribution. Results: A total of 28 subjects completed the study (14 in the safinamide group, 14 in the control group) with comparable baseline characteristics between the two groups (p>0.05). In the within-group analysis, the safinamide group showed significant improvement across all primary outcome parameters (p0.05). In the between-group analysis, the safinamide group demonstrated significantly greater improvements (Δ) in all motor complication parameters (p≤0.001), motor function parameter using Δ UPDRS-II (p
No other version available